Alnylam Pharma (ALNY) Misses Q3 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
CEO Departure Likely to Pressure Alnylam (ALNY) Stock, M&A Possibility Will Likely Fade - Analyst
October 28, 2021 8:41 AM EDTEarlier today, alongside its Q3 report, Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) announced the planned CEO transition of John Maraganore, Ph.D., to Yvonne Greenstreet, at... More
